Histamine dihydrochloride and low-dose interleukin-2 in an emerging landscape of relapse prevention in acute myeloid leukemia
Effective strategies to maintain complete remission in adults with acute myeloid leukemia (AML) are critically needed. Early clinical trials aimed at preventing relapse in the postconsolidation phase explored prolonged chemotherapy, single-agent immunotherapy, and hybrid chemo-immunotherapy, but non...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-06-01
|
| Series: | Therapeutic Advances in Hematology |
| Online Access: | https://doi.org/10.1177/20406207251351086 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850120231858470912 |
|---|---|
| author | Malin S. Nilsson Anna Martner Lovisa Wennström Markus Hansson Fredrik B. Thorén Kristoffer Hellstrand |
| author_facet | Malin S. Nilsson Anna Martner Lovisa Wennström Markus Hansson Fredrik B. Thorén Kristoffer Hellstrand |
| author_sort | Malin S. Nilsson |
| collection | DOAJ |
| description | Effective strategies to maintain complete remission in adults with acute myeloid leukemia (AML) are critically needed. Early clinical trials aimed at preventing relapse in the postconsolidation phase explored prolonged chemotherapy, single-agent immunotherapy, and hybrid chemo-immunotherapy, but none of these approaches produced practice-changing results. More recent trials have identified efficacious remission maintenance strategies, including (1) midostaurin or quizartinib for patients with FLT3 -mutated AML, (2) oral azacitidine for older AML patients, and (3) immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) for younger patients. In this review, we examine key phase III trial and follow-up study results for approved remission maintenance therapies, with a particular focus on HDC/IL-2. We discuss clinical efficacy in relation to patient age and anti-leukemic immunity as well as leukemic cell chemosensitivity, chromosomal integrity, and mutational profiles. Finally, we propose a role for HDC/IL-2 within an evolving landscape of strategies to achieve durable remission in a broader population of AML patients. |
| format | Article |
| id | doaj-art-9223c4ebb1b8412bbd85497fce52ee25 |
| institution | OA Journals |
| issn | 2040-6215 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Hematology |
| spelling | doaj-art-9223c4ebb1b8412bbd85497fce52ee252025-08-20T02:35:24ZengSAGE PublishingTherapeutic Advances in Hematology2040-62152025-06-011610.1177/20406207251351086Histamine dihydrochloride and low-dose interleukin-2 in an emerging landscape of relapse prevention in acute myeloid leukemiaMalin S. NilssonAnna MartnerLovisa WennströmMarkus HanssonFredrik B. ThorénKristoffer HellstrandEffective strategies to maintain complete remission in adults with acute myeloid leukemia (AML) are critically needed. Early clinical trials aimed at preventing relapse in the postconsolidation phase explored prolonged chemotherapy, single-agent immunotherapy, and hybrid chemo-immunotherapy, but none of these approaches produced practice-changing results. More recent trials have identified efficacious remission maintenance strategies, including (1) midostaurin or quizartinib for patients with FLT3 -mutated AML, (2) oral azacitidine for older AML patients, and (3) immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) for younger patients. In this review, we examine key phase III trial and follow-up study results for approved remission maintenance therapies, with a particular focus on HDC/IL-2. We discuss clinical efficacy in relation to patient age and anti-leukemic immunity as well as leukemic cell chemosensitivity, chromosomal integrity, and mutational profiles. Finally, we propose a role for HDC/IL-2 within an evolving landscape of strategies to achieve durable remission in a broader population of AML patients.https://doi.org/10.1177/20406207251351086 |
| spellingShingle | Malin S. Nilsson Anna Martner Lovisa Wennström Markus Hansson Fredrik B. Thorén Kristoffer Hellstrand Histamine dihydrochloride and low-dose interleukin-2 in an emerging landscape of relapse prevention in acute myeloid leukemia Therapeutic Advances in Hematology |
| title | Histamine dihydrochloride and low-dose interleukin-2 in an emerging landscape of relapse prevention in acute myeloid leukemia |
| title_full | Histamine dihydrochloride and low-dose interleukin-2 in an emerging landscape of relapse prevention in acute myeloid leukemia |
| title_fullStr | Histamine dihydrochloride and low-dose interleukin-2 in an emerging landscape of relapse prevention in acute myeloid leukemia |
| title_full_unstemmed | Histamine dihydrochloride and low-dose interleukin-2 in an emerging landscape of relapse prevention in acute myeloid leukemia |
| title_short | Histamine dihydrochloride and low-dose interleukin-2 in an emerging landscape of relapse prevention in acute myeloid leukemia |
| title_sort | histamine dihydrochloride and low dose interleukin 2 in an emerging landscape of relapse prevention in acute myeloid leukemia |
| url | https://doi.org/10.1177/20406207251351086 |
| work_keys_str_mv | AT malinsnilsson histaminedihydrochlorideandlowdoseinterleukin2inanemerginglandscapeofrelapsepreventioninacutemyeloidleukemia AT annamartner histaminedihydrochlorideandlowdoseinterleukin2inanemerginglandscapeofrelapsepreventioninacutemyeloidleukemia AT lovisawennstrom histaminedihydrochlorideandlowdoseinterleukin2inanemerginglandscapeofrelapsepreventioninacutemyeloidleukemia AT markushansson histaminedihydrochlorideandlowdoseinterleukin2inanemerginglandscapeofrelapsepreventioninacutemyeloidleukemia AT fredrikbthoren histaminedihydrochlorideandlowdoseinterleukin2inanemerginglandscapeofrelapsepreventioninacutemyeloidleukemia AT kristofferhellstrand histaminedihydrochlorideandlowdoseinterleukin2inanemerginglandscapeofrelapsepreventioninacutemyeloidleukemia |